EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Adjunctive lumateperone ( ITI ‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial

Trisha Suppes iD, Suresh Durgam, Susan G Kozauer, Richard Chen, Hassan D Lakkis, Robert E Davis, Andrew Satlin, Kimberly E Vanover, Sharon Mates, Roger S McIntyre iD, Mauricio Tohen iD

Bipolar Disorders · 2023

DOI: 10.1111/bdi.13310 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Bipolar Disorders, 2023. Verfasst von Trisha Suppes und 10 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Bipolar Disorder, Major Depressive Disorder, Antipsychotic Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This phase 3, randomized, double‐blind, placebo‐controlled study (NCT02600507) evaluated the efficacy and safety of lumateperone adjunctive therapy to lithium or valproate in patients with bipolar depression.

Methods

Patients (18–75 years) with bipolar I or bipolar II disorder experiencing a major depressive episode (MDE), with inadequate therapeutic response to lithium or valproate, were randomized 1:1:1 to 6 weeks adjunctive therapy with lumateperone 28 mg ( n = 176), lumateperone 42 mg ( n = 177), or placebo ( n = 176). The primary and key secondary efficacy endpoints were change from baseline to Day 43 in Montgomery‐Åsberg Depression Rating Scale (MADRS) Total score and the Clinical Global Impression Scale‐Bipolar Version‐Severity Scale (CGI‐BP‐S) depression subscore. Safety assessments included adverse events, laboratory evaluations, vital signs, extrapyramidal symptoms (EPS), and suicidality.

Results

Patients treated with adjunctive lumateperone 42 mg showed significantly greater improvement compared with adjunctive placebo in MADRS Total score (LS mean difference vs placebo [LSMD], −2.4; p = 0.02) and CGI‐BP‐S depression subscore (LSMD, −0.3; p = 0.01), while adjunctive lumateperone 28 mg showed numerical improvement in MADRS Total score (LSMD, −1.7; p = 0.10) and improvement in the CGI‐BP‐S depression subscore (LSMD, −0.3; p = 0.04). Adjunctive lumateperone treatment was well tolerated; treatment‐emergent adverse events reported at rates >5% and twice placebo for lumateperone 42 mg were somnolence (11.3%), dizziness (10.7%), and nausea (8.5%), with minimal risk of EPS, metabolic abnormalities, or increased prolactin.

Conclusions

Lumateperone 42‐mg treatment adjunctive to lithium or valproate significantly improved depression symptoms and was generally well tolerated in patients with MDEs associated with either bipolar I or bipolar II disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderMajor Depressive DisorderAntipsychotic AgentsHumansValproic AcidLithiumDrug Therapy, CombinationDouble-Blind MethodTreatment OutcomeHeterocyclic Compounds, 4 or More Rings

Stichwörter der Autor:innen

antipsychotic agentbipolar depressionbipolar disorderlumateperone

Substanzen

Valproic AcidLithiumAntipsychotic AgentslumateperoneHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Stanford University School of Medicine, Stanford, California, USA.
  • US Department of Veterans Affairs Palo Alto Healthcare System, Palo Alto, California, USA.
  • Intra-Cellular Therapies, Inc, New York City, New York, USA.
  • Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Trisha Suppes, Roger S McIntyre, Mauricio Tohen

Zitieren

APA

Suppes, T., Durgam, S., Kozauer, S. G., Chen, R., Lakkis, H. D., Davis, R. E., Satlin, A., Vanover, K. E., Mates, S., McIntyre, R. S., & Tohen, M. (2023). Adjunctive lumateperone ( ITI ‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial. Bipolar Disorders. https://doi.org/10.1111/bdi.13310

Vancouver

Suppes T, Durgam S, Kozauer SG, Chen R, Lakkis HD, Davis RE, et al. Adjunctive lumateperone ( ITI ‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial. Bipolar Disorders. 2023. doi:10.1111/bdi.13310

BibTeX
@article{Suppes2023,
  author = {Suppes, Trisha and Durgam, Suresh and Kozauer, Susan G and Chen, Richard and Lakkis, Hassan D and Davis, Robert E and Satlin, Andrew and Vanover, Kimberly E and Mates, Sharon and McIntyre, Roger S and Tohen, Mauricio},
  title = {Adjunctive lumateperone ( ITI ‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial},
  journal = {Bipolar Disorders},
  year = {2023},
  doi = {10.1111/bdi.13310}
}
Kostenlos starten →